Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

Summary

In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.

Timeline

Start

2008-04

Primary completion

2011-03

Completion

2011-03

Drugs

Indications